Preview

Cardiovascular Therapy and Prevention

Advanced search

Role of the individual metabolic syndrome components and heart remodelling progression in women

Abstract

Aim. To analyze the dynamics of heart structure, geometry, and function in women, in accordance with present components of metabolic syndrome (MS). Material and methods. In total, 245 women, comparable by age and blood pressure (BP) levels, were examined: with arterial hypertension (AH), but without dyslipidemia (DL) or obesity (O) (control group, CG; n=100); with AH and DL, but without O (Group 1; n=37); with AH, DL, abdominal O (mean waist circumference, WC, 104,84±15,92 cm), but without carbohydrate metabolism disturbances (Group 2; n=93); with AH, DL, abdominal O and impaired glucose tolerance, IGT (Group 3; n=15); with AH, DL, abdominal O and new-onset Type 2 diabetes mellitus (DM-2) (Group 4; n=22). All participants underwent echocardiography, with the assessment of left ventricular (LV) remodelling indices, oral glucose tolerance test, and serum lipid profile assessment. Results. DL did not demonstrate an independent role in heart structural and functional changes. In women with MS and impaired carbohydrate metabolism (IGT or DM), remodelling was a manifestation of disadaptation. In these patients, increased body mass index (BMI) and plasma glucose levels were associated with impaired systolic function (increased systolic myocardial stress, reduced ejection fraction, and earlier development of heart failure). Conclusion. In women with various combinations of MS components, heart structure and function changes are different. Insulin resistance facilitates the progression of systolic myocardial stress and myocardial contractility reduction. Increased levels of BMI, serum glucose and glycated hemoglobin were associated with impaired systolic function and earlier development of heart failure in women with MS.

About the Authors

E. M. Khurs
Ural State Medical Academy. Yekaterinburg
Russian Federation


A. N. Dmitriev
Ural State Medical Academy. Yekaterinburg
Russian Federation


A. V. Poddubnaya
Ural State Medical Academy. Yekaterinburg
Russian Federation


E. M. Futerman
Ural State Medical Academy. Yekaterinburg
Russian Federation


References

1. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002; 287: 356-9.

2. Mancia G, Bombelli M, Corrao G, et al. Metabolic syndrome in the Pressioni Arteriose Monitorate E Loro Associazioni (PAMELA) study: daily life blood pressure, cardiac damage, and prognosis. Hypertension 2007; 49: 40-7.

3. Hanson RL, Imperatore G, Bennett PH, Knowler WC. Components of the “metabolic syndrome” and incidence of type 2 diabetes. Diabetes 2002; 51: 3120-7.

4. Resnick HE, Hones K, Ruotolo G, et al. Insulin resistance, the metabolic syndrome, and of incident cardiovascular disease in nondiabetic American Indians: the Strong Heart Study. Diabetes Care 2003; 26: 861-7.

5. Schmidt MI, Duncan BB, Bang H, et al. Identifying individuals at high risk for diabetes: The Atherosclerosis Risk in Communities study. Diabetes Care 2005; 28: 2013-8.

6. Vasan RS, Beiser A, Seshadri S, et al. Residual lifetime risk for developing hypertension in middle-aged women and men. The Framingham Heart Study. JAMA 2002; 287: 1003-10.

7. Шляхто Е.В., Конради А.О. Ремоделирование сердца при гипертонической болезни. Сердце 2002; 1(5): 232-4.

8. Levy D, Garrison RJ, Savage DD, et al. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. New Engl J Med 1990; 322: 1561-6.

9. Eberly LE, Prineas R, Cohen JD, et al. Metabolic Syndrome: Risk factor distribution and 18-year mortality in the Multiple Risk Factor Intervention Trial. Diabetes Care 2006; 29(1): 123-30.

10. Ingelsson E, Arnlov J, Lind L, Sundstrom J. The metabolic syndrome and risk for heart failure in middle-aged men. Heart 2006; 12: 106-12.

11. Aijaz В. Abnormal Cardiac Structure and Function in the Metabolic Syndrome: A Population-Based Study. Mayo Clin Proc 2008; 83: 1350-7.

12. Александров Ан.А., Поддубская Е.А., Кухаренко С.С. и др. Геометрия левого желудочка, артериальная гипертония и ожирение: поиск новых путей профилактики. Профил забол укреп здор. Москва “Медиасфера” 2003; 5: 6-11.

13. Pohost GM, Dell’Italia LJ, Kortright E, et al. Marked Regional Left Ventricular Heterogeneity in Hypertensive Left Ventricular Hypertrophy Patients: A Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) Cardiovascular Magnetic Resonance and Echocardiographic Substudy. Hypertension 2008; 52: 279-86.

14. Schillaci G, Pirro M, Vaudo G, et al. Prognostic value of the metabolic syndrome in essential hypertension. JACC 2004; 43: 1817-22.

15. Malik S, Wong ND, Franklin SS, et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation 2004; 110: 1245-50.

16. Hunt KJ, Resendez RG, Williams K, et al. Cholesterol Education Program versus World Health Organization metabolic syndrome in relation to all-cause and cardiovascular mortality in the San Antonio Heart Study. Circulation 2004; 110: 1251-7.

17. Wilson PW, Kannell WB, Silbershatz H, D’Agostino RB. Clustering of metabolic factors and coronary heart disease. Arch Intern Med 1999; 159: 1104-9.

18. Lang RM, Bierig M, Devereux RB, et al. Recommendations for chamber quantification. Guidelines. Eur J Echocardiography 2006; 7: 79-108.

19. Devereux RB, Reichek N. Echocardiographic determination of left ventricular mass in man: anatomic validation of the method. Circulation 1977; 55: 613-8.

20. Devereux RB, Alonso DR, Lutas EM, et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J CardioL 1986; 57: 450-8.

21. Devereux RB. Evaluation of cardiac structure and function by echocardiography and other noninvasive techniques. Hypertension: Pathophysiology, Diagnosis, Treatment. New York, NY: Raven Press Publishers 1990; 1479-92.

22. Simone G de, Devereux RB, Roman MJ, et al. Relation of obesity and gender to left ventricular hypertrophy in normotensive and hypertensive adults. Hypertension 1994; 23: 600-6.

23. Nagueh ShF, Appleton ChP, Gillebert ThC, et al. Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography. J Am Soc Echocardiog 2009; 22 (2): 107-33.

24. Gale EAM. Should we dump the metabolic syndrome?: Yes BMJ 2008; 336: 640-1.

25. Kahn R. Metabolic Syndrome: Is It a Syndrome? Does It Matter? Circulation 2007; 115: 1806-11.

26. Мамедов М.Н. Опыт комбинированной антигипертензивной терапии у больных с метаболическим синдромом. РКЖ 2006; 4(60): 69-74.


Review

For citations:


Khurs E.M., Dmitriev A.N., Poddubnaya A.V., Futerman E.M. Role of the individual metabolic syndrome components and heart remodelling progression in women. Cardiovascular Therapy and Prevention. 2010;9(8):17-22. (In Russ.)

Views: 545


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1728-8800 (Print)
ISSN 2619-0125 (Online)